CClinicalTrials.gg
RecruitingNCT06775821Updated Jan 15, 2025

Epidemiology of Abdominal Aortic Aneurysm With Concomitant Primary Lung Cancer

An observational study in Abdominal Aortic Aneurysm, Primary Lung Cancer and Prevalence, sponsored by First Affiliated Hospital of Kunming Medical University. Recruiting at 2 sites in China. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by First Affiliated Hospital of Kunming Medical University · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years later.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
2,000
Ages
20 Years to 90 Years
Sex
All
01

Study summary

Retrospective clinical case studies in recent years have shown that most cases of lung cancer and abdominal aortic aneurysm (AAA) are detected at the same time and that there is a wide variation in the prevalence of AAA in patients with primary lung cancer reported in the literature, with some papers suggesting as high as 11%, suggesting that there may be a relationship between the prevalence of the two diseases. However, its exact incidence and mechanism are unknown. Accurate prevention of AAA in patients with primary lung cancer requires more in-depth studies. To solve the above problems, a multi-center prospective epidemiological investigation and mechanism study on the association of AAA in primary lung cancer combined has become particularly urgent. The results of the study will be of great significance for the follow-up treatment and prognosis of lung cancer patients as well as the improvement of long-term survival rate of lung cancer patients, and will also provide scientific basis and clinical guidance for the screening and prevention of AAA in lung cancer patients.

Read the detailed description
  1. research purpose: This study collected detailed basic information, lifestyle habits, past medical history, and laboratory indicators from 2000-3000 outpatient patients with primary lung cancer for data analysis and long-term follow-up. The study analyzed the related factors of lung cancer complicated with AAA, providing direct scientific evidence to better guide lung cancer patients in screening for AAA, identifying common high-risk factors for lung cancer patients complicated with AAA, providing clinical guidance for the prevention of AAA, and reducing the risk of AAA rupture. The research results are of great significance for the subsequent treatment and prognosis of lung cancer patients, as well as improving the long-term survival rate of lung cancer patients. They will also provide scientific basis and clinical guidance for the screening and prevention of AAA in lung cancer patients. Early detection and treatment of AAA can reduce the risk of AAA rupture, greatly improve the prognosis of lung cancer patients with AAA, and enhance their quality of life.
  2. research population: The research subjects are patients diagnosed with primary lung cancer at the Third Affiliated Hospital of Kunming Medical University and the First Affiliated Hospital of Kunming Medical University from 1st October 2022 to 30 st April 2025. The expected sample size is about 2000 people, and the age of patients is 20-90 years old. Collect detailed epidemiological data and long-term follow-up data, conduct statistical analysis, and conduct epidemiological investigations.
  3. Epidemiological data collection:

3.1 Basic Information: name, gender, ethnicity, age, height, weight, hometown, occupation, education level, ID card, phone number, and medical record number.

3.2 Behavioral Life Information:Whether smoking, smoking index, alcohol consumption, alcohol content and quantity consumed, history of exposure to asbestos products, dietary habits, and history of dust exposure.

3.3 Past medical history and family genetic history: Presence of hypertension, degree of hypertension, blood pressure control medications, and blood pressure control; diabetes mellitus, blood glucose control medications, and blood glucose control; hyperlipidemia, elevated lipid composition, lipid control medications, and lipid control; urologic disorders; family history of vascular disorders; and family history of oncologic disorders.

3.4 Laboratory information: Blood pressure, fasting blood glucose, glycosylated hemoglobin Total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C).

3.5 Follow-up information:

  1. Information related to primary lung cancer: types of lung tumors (squamous cell carcinoma, adenocarcinoma, small cell/neuroendocrine/other); Staging of lung tumors (stages I, II, III, IV); CNM staging; Differentiation results of lung tumors; Immunohistochemical staining results; Tumor markers (outliers); Tumor genes (outliers); The treatment methods for lung tumors (surgery, radiotherapy, chemotherapy, molecular targeting, immunity, biological therapy, neoadjuvant chemotherapy); Surgical time and bleeding volume.
  2. Information related to abdominal aortic aneurysm: whether it is complicated with abdominal aortic aneurysm; Is there a concomitant iliac artery aneurysm; Whether to undergo surgical treatment; Surgical treatment methods (endovascular repair of abdominal aortic aneurysm, open surgery); Surgical time and bleeding volume.
  3. Patient prognosis: last follow-up time, time of lung tumor recurrence, whether death occurred, and cause of death.

4.Data entry and analysis At the Department of Thoracic Surgery of the First Affiliated Hospital of Kunming Medical University and the Department of Thoracic Surgery of the Third Affiliated Hospital of Kunming Medical University, patient basic information, laboratory tests, and treatment plans are obtained and filled out from the hospital's medical record system. Epidemiological survey questions are collected at the patient's bedside using a question and answer format to ensure the accuracy and reliability of the epidemiological survey information. All collected data is organized and encoded using REDCap( https://www.wcrcnet.cn/redcap/ )Perform data entry. IBM SPSS Statistics 22 will be used to analyze the entered data and identify the risk factors for primary lung cancer combined with AAA.

02

Conditions studied

  • Abdominal Aortic Aneurysm
  • Primary Lung Cancer
  • Prevalence

Keywords

  • Abdominal Aortic Aneurysm
  • primary lung cancer
  • epidemiological studies
  • prevalence
03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

First Affiliated Hospital of Kunming Medical University is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The selected subjects for the study were all patients diagnosed with primary lung cancer at the First Affiliated Hospital of Kunming Medical University and the Third Affiliated Hospital of Kunming Medical University from 1st October 2022 to 30 st April 2025, with an estimated sample size of about 2000 people. Detailed epidemiological data and long-term follow-up data were collected and analyzed, and epidemiological investigations were conducted.

Inclusion criteria

  • Patients diagnosed with primary lung cancer through clinical or pathological examination

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with primary lung cancer who refuse to undergo abdominal aortic imaging screening.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
2,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Primary lung cancer with concomitant abdominal aortic aneurysm

    Device: Ultrasound or CT of the abdominal aorta

Interventions

  • DeviceUltrasound or CT of the abdominal aorta

    Patient underwent ultrasound or CT of the abdominal aorta

06

What researchers measure

Primary outcomes

  1. Incidence of abdominal aortic aneurysm in patients with primary lung cancer

    Incidence of abdominal aortic aneurysm in patients with primary lung cancer

    Time frame: 2022-10-01 to 2025-04-30

Secondary outcomes

  1. Epidemiological analysis

    Common pathogenic factors of primary lung cancer with concomitant abdominal aortic aneurysm

    Time frame: 2022-10-01 to 2025-04-30

07

Study locations

2 of 2 sites recruiting
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650000, China
    • Yun-fei shi, Mphil · Contact · 13908716639
    Recruiting
  • The Third Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650000, China
    • Xu-dong Xiang, MPhil · Contact · 13108519813
    Recruiting
08

References and documents

Publications

  • Sakalihasan N, Michel JB, Katsargyris A, Kuivaniemi H, Defraigne JO, Nchimi A, Powell JT, Yoshimura K, Hultgren R. Abdominal aortic aneurysms. Nat Rev Dis Primers. 2018 Oct 18;4(1):34. doi: 10.1038/s41572-018-0030-7. PubMed 30337540 ↗
  • Schanzer A, Oderich GS. Management of Abdominal Aortic Aneurysms. N Engl J Med. 2021 Oct 28;385(18):1690-1698. doi: 10.1056/NEJMcp2108504. No abstract available. PubMed 34706173 ↗
  • Golledge J. Abdominal aortic aneurysm: update on pathogenesis and medical treatments. Nat Rev Cardiol. 2019 Apr;16(4):225-242. doi: 10.1038/s41569-018-0114-9. PubMed 30443031 ↗
  • Alnahhal KI, Urhiafe V, Narayanan M, Irshad A, Salehi P. Prevalence of abdominal aortic aneurysms in patients with lung cancer. J Vasc Surg. 2022 May;75(5):1577-1582.e1. doi: 10.1016/j.jvs.2021.09.037. Epub 2021 Oct 8. PubMed 34634421 ↗
  • Wiles B, Comito M, Labropoulos N, Santore LA, Bilfinger T. High prevalence of abdominal aortic aneurysms in patients with lung cancer. J Vasc Surg. 2021 Mar;73(3):850-855. doi: 10.1016/j.jvs.2020.05.069. Epub 2020 Jul 2. PubMed 32623102 ↗
  • Cho HJ, Yoo JH, Kim MH, Ko KJ, Jun KW, Han KD, Hwang JK. Risk of various cancers in adults with abdominal aortic aneurysms. J Vasc Surg. 2023 Jan;77(1):80-88.e2. doi: 10.1016/j.jvs.2022.03.896. Epub 2022 Jul 15. PubMed 35850163 ↗
  • Hohneck A, Shchetynska-Marinova T, Ruemenapf G, Pancheva M, Hofheinz R, Boda-Heggemann J, Sperk E, Riffel P, Michels J, Borggrefe M, Akin I, Sigl M. Coprevalence and Incidence of Lung Cancer in Patients Screened for Abdominal Aortic Aneurysm. Anticancer Res. 2020 Jul;40(7):4137-4145. doi: 10.21873/anticanres.14413. PubMed 32620663 ↗
  • Harthun NL, Lau CL. The incidence of pulmonary neoplasms discovered by serial computed tomography scanning after endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2011 Mar;53(3):738-41. doi: 10.1016/j.jvs.2010.09.066. Epub 2010 Dec 3. PubMed 21129909 ↗
  • Lederlin M, Tredaniel J, Priollet P. [Why screen for lung cancer in patients with arterial disease?]. J Mal Vasc. 2015 Dec;40(6):359-64. doi: 10.1016/j.jmv.2015.07.001. Epub 2015 Aug 12. French. PubMed 26276562 ↗
  • Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ; ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014 Nov 1;35(41):2873-926. doi: 10.1093/eurheartj/ehu281. Epub 2014 Aug 29. No abstract available. Erratum In: Eur Heart J. 2015 Nov 1;36(41):2779. doi: 10.1093/eurheartj/ehv178. PubMed 25173340 ↗
  • Scorza R, Ghilardi G, De Monti M, Sgroi G. [Current knowledge and unresolved problems in the pathogenesis of abdominal aortic aneurysm]. Minerva Cardioangiol. 1994 Sep;42(9):417-27. Italian. PubMed 7991161 ↗

Study documents

  • Informed consent form · Jan 10, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided — If necessary, upload to make individual participant data (IPD) available to other researchers after the research is completed

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06775821
Lead sponsor
First Affiliated Hospital of Kunming Medical University
Collaborators
The Third Affiliated Hospital of Kunming Medical University, Kunming Medical University
Responsible party
Dr. Kai-Xiong QING (Associate Professor, First Affiliated Hospital of Kunming Medical University) — Principal investigator
First posted
Jan 15, 2025
Start date
Oct 1, 2022
Primary completion
Apr 30, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
Jan 15, 2025

Study contacts

Kai-xiong Qing, Ph.D.
Contact
davidqkx@gmail.com
15908855311
Qian Zhu, MBBS
Contact
zhuqian0711@163.com
15191066760
Xu-Dong Xiang, MPhil
study director · The Third Affiliated Hospital of Kunming Medical University
Ding-yun You, Ph.D.
study director · Kunming Medical University
Yun-fei Shi, MPhil
study director · First Affiliated Hospital of Kunming Medical University
Gui-ming Liu, MBBS
principal investigator · The Third Affiliated Hospital of Kunming Medical University
Qing-yan Ma, MBBS
principal investigator · Kunming Medical University
Qian Zhu, MBBS
principal investigator · The Third Affiliated Hospital of Kunming Medical University
Kai-xiong Qing, ph.D.
study chair · The Third Affiliated Hospital of Kunming Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion